Single hs-cTnT Measure, Non-Ischemic ECG Can Rule Out AMI

Share this content:
Single hs-cTnT Measure, Non-Ischemic ECG Can Rule Out AMI
Single hs-cTnT Measure, Non-Ischemic ECG Can Rule Out AMI

WEDNESDAY, April 19, 2017 (HealthDay News) -- For adults presenting to the emergency department with chest pain, a single high-sensitivity assay for cardiac troponin T (hs-cTnT) below the limit of detection and a non-ischemic electrocardiogram (ECG) can rule out acute myocardial infarction (AMI), according to a meta-analysis published online April 18 in the Annals of Internal Medicine.

John W. Pickering, Ph.D., from the University of Otago Christchurch in New Zealand, and colleagues examined cohort studies involving adults presenting to the emergency department with possible acute coronary syndrome to estimate the ability of a single hs-cTnT concentration below the limit of detection and a non-ischemic ECG to rule out AMI. Data were included for 9,241 patients in 11 cohort studies.

The researchers found that 30.6 percent of patients were classified as low risk. Overall, 0.5 percent of the low-risk patients had AMI. In individual studies, the sensitivity of the risk classification for AMI varied from 87.5 to 100 percent, with pooled estimated sensitivity of 98.7 percent. For 30-day major adverse cardiovascular events the sensitivity varied from 87.9 to 100 percent, with pooled sensitivity of 98.0 percent. There were no deaths reported among low-risk patients.

"A single hs-cTnT concentration below the limit of detection in combination with a non-ischemic ECG may successfully rule out AMI in patients presenting to emergency departments with possible emergency acute coronary syndrome," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »